Citations

Clear

146 citation(s) found for "Simpson, M".

Abstract P045: Differential Associations of Inflammation and Cognitive Function in African and European Americans
Simpson, Brittany , Griswold, Michael , Bridges, J. M. , Peyser, Patricia A. , Bielak, Lawrence F. , Windham, B. Gwen , Turner, Stephen T. , Mosley, Thomas H.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 127 | Issue: suppl_12 | Pages: No page available

10.1161/circ.127.suppl_12.ap045 Get It

Dementia affects approximately 5 million people in the United States and cost $183 billion in 2011, with African Americans (AA) experiencing a disproportionate burden of dementia compared to European Americans (EA). Inflammation is considered by many to be a potential mediator in the development of cognitive dysfunction. High sensitivity C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α), increasingly measured by the soluble TNF receptors 1 & 2 (sTNFRI1, sTNFR2), are among the most frequently cited inflammatory markers associated with dementia and are also elevated in vascular disease. Few studies have compared associations of inflammatory markers with cognitive function in EA and AA. We examined the association of CRP, sTNFR1 and sTNFR2 with cognitive function using detailed neuropsychological assessments in the Genetic Epidemiology Network of Arteriopathy (GENOA)-Genetics of Microangiopathic Brain Injury (GMBI) participants, a cohort considered at high risk of vascular disease due to family history (> 2 individuals in sibships with hypertension at age <60 years) and high prevalence rates of hypertension (74%), diabetes (27%), and obesity (51%). Cognitive function was measured across 5 cognitive domains: global cognitive function, processing speed, language, memory, and executive function. In AA, higher sTNFR2 was associated with poorer performance across all five domains. Higher sTNFR1 and CRP were associated with slower processing speed. In EA, higher sTNFR1 was associated with slower processing speed. CRP and sTNFR2 were not associated with cognitive function in EA. Inflammatory markers in this cohort were associated differentially across cognitive domains in AA and EA, and may reflect racial differences in vascular responses to inflammation.
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy
Gustafson, Michael P. , Wheatley, Courtney M. , Gastineau, Dennis A. , Johnson, Bruce D. , Wheatley-Guy, Courtney M, Rosenthal, Allison C, Rosenthal, Allison , Katsanis, Emmanuel , Simpson, Richard J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 2, 2021 | Volume: 9 | Issue: 7 | Pages: e001872

10.1136/jitc-2020-001872 | PMID 34215686 Get It

The remarkable success of cancer immunotherapies has provided new hope to cancer patients. Unfortunately, a significant proportion of patients remain unable to respond to immunotherapy or maintain durable clinical responses. The lack of objective responses likely results from profound immune dysfunction often observed in patients with cancer. There is substantial evidence that exercise and physical activity can reduce incidence and improve outcomes in cancer patients. As the immune system is highly responsive to exercise, one potential avenue to improve immune function is through exercise and physical activity. A single event of dynamic exercise results in the substantial mobilization of leukocytes with increased functional capacities into the circulation. Chronic, or long-term, exercise leads to higher physical fitness in terms of greater cardiorespiratory function and/or muscle strength and endurance. High aerobic capacity, as measured by maximal oxygen uptake, has been associated with the reduction of dysfunctional T cells and improvements in the abundance of some T cell populations. To be sure, however, the mechanisms of exercise-mediated immune changes are both extensive and diverse. Here, we examine the evidence and theorize how acute and chronic exercise could be used to improve responses to cancer immunotherapies including immune checkpoint inhibitors, dendritic cell vaccines, natural killer cell therapies, and adoptive T cell therapies such as chimeric antigen receptor (CAR) T cells. Although the parameters of optimal exercise to yield defined outcomes remain to be determined, the available current data provide a compelling justification for additional human studies and clinical trials investigating the adjuvant use of exercise in immuno-oncology.
Got 15? Try Faculty Development on the Fly: A Snippets Workshop for Microlearning
Bowler, Carrie , Foshee, Cecile , Haggar, Faye L. , Schroedl, Clara , Billings, Heather , Billings, Heather , Schroedl, Clara , Billings, Heather , Bowler, Carrie A , Billings, Heather , Simpson, Deborah

Mayo Clinic

MedEdPORTAL | June 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11161 | PMID 34189261 Get It

Genetic Variation and Recurrent Haplotypes on Chromosome 6q23-25 Risk Locus in Familial Lung Cancer
Musolf, Anthony M. , Simpson, Claire L. , Moiz, Bilal A., Pikielny, Claudio W. , Middlebrooks, Candace D., Mandal, Diptasri , Andrade, Mariza de , Cole, Michael D. , Gaba, Colette , Yang, Ping , You, Ming , Li, Yafang , Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Pinney, Susan M. , Bailey‐Wilson, Joan E. , de Andrade, Mariza , Amos, Christopher I , Wilson, Richard K , Yang, Ping , Pinney, Susan M , Amos, Christopher I.

Mayo Clinic

Cancer Research | April 14, 2021 | Volume: 81 | Issue: 12 | Pages: 3162-3173

10.1158/0008-5472.can-20-3196 | PMID 33853833 Get It

Abstract Although lung cancer is known to be caused by environmental factors, it has also been shown to have genetic components, and the genetic etiology of lung cancer remains understudied. We previously identified a lung cancer risk locus on 6q23-25 using microsatellite data in families with a history of lung cancer. To further elucidate that signal, we performed targeted sequencing on nine of our most strongly linked families. Two-point linkage analysis of the sequencing data revealed that the signal was heterogeneous and that different families likely had different risk variants. Three specific haplotypes were shared by some of the families: 6q25.3-26 in families 42 and 44, 6q25.2-25.3 in families 47 and 59, and 6q24.2-25.1 in families 30, 33, and 35. Region-based logarithm of the odds scores and expression data identified the likely candidate genes for each haplotype overlap: ARID1B at 6q25.3, MAP3K4 at 6q26, and UTRN (6q24.1) and PHACTR2 (6q24.2). Further annotation was used to zero in on potential risk variants in those genes. All four genes are good candidate genes for lung cancer risk, having been linked to either lung cancer specifically or other cancers. However, this is the first time any of these genes has been implicated in germline risk. Functional analysis of these four genes is planned for future work. Significance: This study identifies four genes associated with lung cancer risk, which could help guide future lung cancer prevention and treatment approaches.
High-grade Transformation/Dedifferentiation in Salivary Gland Carcinomas: Occurrence Across Subtypes and Clinical Significance
Skálová, Alena , Simpson, Roderick H.W., Poorten, Vincent Vander , Willems, Stefan M. , Olsen, Kerry D., Ferlito, Alfio , Vander Poorten, Vincent , Leivo, Ilmo V.V. , Hellquist, Henrik B. , Agaimy, Abbas , Stenman, Göran , Bishop, Justin A. , Franchi, Alessandro , Hernandez‐Prera, Juan C. , Slouka, David

Mayo Clinic

Advances in Anatomic Pathology | March 24, 2021 | Volume: 28 | Issue: 3 | Pages: 107-118

10.1097/pap.0000000000000298 | PMID 33825717 Get It

High-grade transformation (HGT) or dedifferentiation has been described in a variety of salivary gland carcinomas, including acinic cell carcinoma, secretory carcinoma, adenoid cystic carcinoma, epithelial-myoepithelial carcinoma, polymorphous adenocarcinoma, low-grade mucoepidermoid carcinoma, and hyalinizing clear cell carcinoma. High-grade (HG) transformed tumors are composed of a conventional low-grade component characterized by specific microscopic and immunohistochemical features for the given entity, intermingled with or juxtaposed to areas of HG morphology. This is usually either poorly differentiated adenocarcinoma, carcinoma not otherwise specified, or undifferentiated carcinoma, in which the original line of differentiation is lost. The HG component is composed of solid nests of anaplastic cells with large vesicular pleomorphic nuclei, prominent nucleoli, and abundant cytoplasm. Frequent mitoses and extensive necrosis may be present. The Ki-67 labeling index is consistently higher in the HG component. The molecular genetic mechanisms responsible for HGT of salivary gland carcinomas are largely unknown, though p53 inactivation and human epidermal growth factor receptor 2 overexpression and/or gene amplification have been demonstrated in the HG component in a few examples, the frequency varies for each histologic type. Salivary gland carcinomas with HGT are more aggressive than conventional carcinomas, with a higher local recurrence rate and a poorer prognosis. They have a high propensity for cervical lymph node metastasis suggesting a need for a wider resection and neck dissection. HGT of salivary gland carcinoma can occur either at initial presentation or less commonly at the time of recurrence, sometimes following postoperative radiotherapy. The potential for HGT in almost any type of salivary gland carcinoma warrants a thorough sampling of all salivary gland malignancies to prevent oversight of a HG component.
Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries
Russotto, Vincenzo , Laffey, John G. , Tassistro, Elena , Camporota, Luigi , Higgs, A. , Putensen, Christian , Agvald‐Öhman, Christina, Bokums, Kristaps, Brewster, David , Rossi, Emanuela , Fumagalli, Roberto , Pesenti, Antonio, Investigators, INTUBE Study, Ahmed, Hazem , Adhikari, Neill K. J. , Agrawal, Kehari, Agrawal, Nipun , Aguirre-Bermeo, Hernán , Agvald-Öhman, Christina, Ahmad, Meraj, Ajami, Samareh, Akhtar, Shazia N., Alghamdi, Adnan, Alhadi, Abdulmueti , Ali, Syed Muhammad Adnan , Ali, Mohd N., Alias, Anita, Alonso, Julio, Montenegro, Diana Alvarez, Aman, Rubina, Anstey, Matthew , Αrnaoutoglou, Eleni , Baccari, Laura, Baliga, Nishanth, Manjunath, Ramya Ballekatte, Bamane, Shrirang, Bandert, Anna , Bartholdy, Roland, Baturova, Vera , Bellissima, Agrippino , Belsky, Vladislav, Bendre, Prashant, Benini, Annalisa, Besset, Sébastien , Bhattacharyya, Mahuya , Bielański, Piotr, Bigatello, Luca M., Boissier, Florence , Bonney, Iwona, Bowen, David , Boyer, Alexandre, Broman, Lina , Bruel, Cédric , Brunin, Yannick, Bugedo, Guillermo , Calamai, Italo , Campos, Patricia , Canavosio, Federico Giovanni , Cascella, Marco , Catorze, Nuno , Champigneulle, Benoît , Chandwani, Juhi, Chaurasia, Satish, Chawla, Rajesh , Chawla, Aakanksha, Cheetham, Olivia, Chemouni, Frank , Kiok, Lee Chew, Chimunda, Timothy , Chiu, Ching‐Tang , Chiumiento, Fernando, Chudeau, Nicolas , Colica, Sandra, Colin, Gwenhaël , Constantin, Jean‐Michel , Contou, Damien , Costa, Paulo F., Costa, Vasco , Cracchiolo, Andrea, Crone, Petra, Cunha, Rui Pedro, Radivojević, Renata Curić , Dash, Sampat, Pascale, Gennaro De , Torre, Valentina Della, Caprio, Barbara Di, Dimitropoulou, Aikaterini, Edmunds, Christopher , El-Fellah, Nadia, Elhadi, Ahmed , Escudero-Acha, P. , Espinoza, Missael, Esposito, Clelia, Fabretti, Fabrizio, Fein, Daniel , Ferluga, Massimo, Ferré, Alexis , Ferrier, Janet, Flaksa, Marek, Flores, Fernando , Gonzalez, Jesus Flores, Fuentes, Xavier Fonseca , Francis, Roland C. E. , Franco, Daniela G., Franczyk, Pawel, Furman, Mikhail, Gałkin, Piotr, Aguilera, Maria F. García, Garofalo, Eugenio , Gatward, Jonathan, Ghula, Mohamed , Giacomucci, Angelo , Giovannini, Ilaria , Gnanadurai, Kingsly Robert, Godet, Thomas, Fernandez, Gemma Goma , González, María del Carmen Martín, González, Daira, Gopalakrishna, Kadarapura Nanjundaiah , Gottesman, Eric , Gros, Alexandre, Gupta, Manish , Gupta, Kulbhusahn, Hamid, Tarikul , Hamzaoui, Olfa, Hannesdottir, Katrin, Hasan, Shahnaz, Hossain, Mozaffer, Hossein, Sazzad, Hraiech, Sami , Hypes, Cameron, Alkhumsi, Soad Imhmed R., Islam, Motiul, Ismail, Muhamad A., Ivančan, Višnja , Jacquier, Sophie , Jagiasi, Bharat, Jain, Nikhilesh , Jamaluddin, Muhamad Fadhil Hadi, Jeswani, Deepak , Jeswani, Deepti, Jha, Simant , Jones, Benjamin , Jozwiak, Mathieu , Jumić, Aleksandra, Kamp, Oliver , Karametos, Ilias, Karelov, Alexey, Kaufman, David A. , Kaushik, Shuchi, Kesavarapu, Subba R., Khaled, Ala , Khalidah, Hapiz, Khunteta, Sudhir , Kindgen‐Milles, Detlef , Korula, Sara , Kothekar, Amol , Koul, Salman S., Krog, Ditte, Kuellmar, Mira, Kuragayala, Swarna Deepak , Kyparissi, Aikaterini, Labarca, Gonzalo , Lalwani, Jaya, Landaverde, Antonio, Lehr, Andrew , Leonor, Tiago, Licciardi, A, Nava, Claudia L. Lopez, Gallardo, Luis R. Loza, Lungu, Ramona , Luzi, Annalisa, Ma, Wuhua , Μakris, Alexandros , Maheshwarappa, Harish Mallapura , Maraffi, Tommaso , Marcelli, Maria Elena, Mariano, Karim, Marin, Nathalie, Martin, Maëlle, Gonzalez, Mayra Martinez, Matas, Marijana , Matos, Dubier, Maugeri, Jessica Giuseppina , Mazlan, Mohd Zulfakar , Meersch, Melanie , Meher, Ranjan, Mehesry, Tasneem H., Meirik, Maria, Dessap, Armand Mekontso , Mensah, Kwabena , Mercier, Emmanuelle, Midya, Abhirup, Mihaljević, Slobodan , Mirouse, Adrien , Mishra, Prasanna K. , Mistry, Ravi , Moguš, Mate, Nordin, Norbaniza Mohd, Samat, Noryani Mohd, Montini, Luca, Moro, Valeria, Tutillo, Diego Morocho , Mrinal, Sircar, Mudyna, Wojciech, Munta, Kartik, Munusamy, Satheesh , Musso, Stefania, Muttini, Stefano , Irtiza, Ismail Nahla, Nakou, Evi, Narkhede, Amit , Nates, Joseph, Nespoli, M, Nespoli, Francesca, Nikitenko, Artem, Nogueira, Carla, O'Grady, Ross, Odeyemi, Yewande , Ohlsson, Annika , Orsello, Alberto, Palaniswamy, Vijayanand , Palma, Daniela Maria , Palmese, Salvatore , Leal, Jesus N. Pantoja, Papandreou, E., Papanikolaou, Metaxia, Patel, Mayur , Pavlek, Mario , Pedrotti, Niccolò , Hwa, Ngu Pei, Pelagalli, Lorella, Ruiz, Miryam Pérez, Persson, Elin, Petsiou, Athanasia, Philippard, Francois, Piegat, Mariusz, Pili‐Floury, Sébastien, Pinto, Márcia , Piton, Gaël , Plantefève, Gaëtan , Pouplet, Caroline, Pouriki, Sofia, Pradella, Andrea , Prashant, Kumar , Quayle, Alice, Rahmani, Lua S. , Randall, Ian , Ray, Banambar , Reza, Syed T., Ricard, Jean Damien, Riva, Ivano, Rona, Roberto , Rosell, Jon, Rowley, Rebecca, Rumschuessel, Kay, Rundo, Annalisa, Russo, Pierpaolo, Sahu, Samir, Salmon-Gandonnière, Charlotte, Roman, Nandyelly San Juan, Sandefur, Benjamin J. , Santoro, Lida, Sanyal, Rhik, Saravanabavan, Lakshmikanthcharan , Shah, Bhagyesh, Shah, Mehul , Shin, Ming-Hann, Simpson, Shannon, Sinah, Ayush, Singh, D. K., Singh, Nitesh , Singh, Lalit, Skowronski, Lukasz , Sosa, Miguel A. Gama , Spadaro, Savino , Spångfors, Martin , Sperber, Jesper , Spina, Rosario, Srivastava, Anand , Steel, Andrew, Suárez-de-la-Rica, Alejandro , Kumar, Singh Sujeet, Sundrani, Omprakash, Sunil, Nilu, Suparna, Bharadwaj, Surath, Manimala R., Syed, Yadullah, Sztrymf, Benjamin , Tarantino, Stefano, Tileli, Maria, Castro, Hugo Arturo Tirapé , Toledo-Salinas, Otoniel , Tramarin, Jacopo, Tsiftsis, D , Tucić, Iva , León, Jose A. Tutillo, Tutino, Lorenzo, Tyagi, Vijay, Vagdatli, Kyriaki, Varkey, Sneha, Vera, Magdalena , Seth, Magnus Von, Wahlström, C.-G., Ismail, Wan Nasrudin Wan, Winiszewski, Hadrien , Wu, Lun , Zani, Gianluca , Zarka, Jonathan , Zhao, Dawn, Zlotnik, Diane , Bauer, Philippe, Laffey, John G , Labarca, Gonzalo , Alhadi, Abdulmueti , Myatra, Sheila Nainan , Antolini, Laura , Bauer, Philippe R. , Lascarrou, Jean-Baptiste , Szuldrzynski, Konstanty S. , Pelosi, Paolo , Sorbello, Massimiliano , Greif, Robert , Chalkias, Athanasios F. , Pesenti, Antonio, Foti, Giuseppe , Bellani, Giacomo , Investigators, INTUBE Study, Agvald-Öhman, Christina, Ahmad, Meraj, Almekhlafi, Ghaleb A. , Aragão, Irene , Azoulay, Élie , Basto, Marta Lima , Besset, Sebastien, Boni, Elisa, Brazzi, Luca , Broman, Lina, Browne, Alexander, Cappellini, Iacopo , Chao, Anne , Chien, Jung‐Yien , Chou, Nai‐Kuan , Cortegiani, Andrea , Costamagna, Andrea , Cotoia, Antonella , Cracchiolo, Andrea N., Das, Amit, Rosa, Silvia De , Sorbo, Lorenzo Del , Fenza, Raffaele Di , Giacinto, Ida Di , Dudda, Marcel , Ehrentraut, Stefan , Elhadi, Muhammed , Fernandes, Marco, Flores, Fernando, Frat, Jean-Pierre , Fusari, Maurizio , Moraes, Alice Gallo de , Gammaldi, Renato , Gaszynski, Tomasz M , Godet, Thomas , Goffi, Alberto , González-Castro, A. , Guervilly, Christophe , Guitton, Christophe , Huang, Chun‐Kai , Jankowski, Miłosz , Jones, Laura, Karelov, Alexey, Katsoulis, P. , Kaye, Callum T. , Khalidah, Hapiz, Khan, Akram , Ku, Shih‐Chi , Kuo, Lu-Cheng , Lalwani, Jaya, Laserna, Andrés , Lee, Chien‐Chang , Legriel, Stéphane , Li, Yongxing , Licciardi, Anna Lisa, Litton, Edward , Ломиворотов, В. В. , Longhini, Federico , Магомедов, М. А. , Геннадьевна, Марова Надежда , Maseda, Emilio , Mastroianni, Fiore , Michálek, Pavel , Mishra, Prasanna, Mistry, Ravi, Montini, Luca , Montrucchio, Giorgia Giuseppina , Mosier, Jarrod , Mudyna, Wojciech, Müller, Grégoire , Munta, Kartik, Musso, Stefania, Nakou, Evi, Nates, Joseph L. , Nogueira, Carla, Leal, Jesús Nicolás Pantoja, Papandreou, Eleni, Parotto, Matteo , Persson, Elin, Pezzi, Angelo , Philip, Sam, Pinciroli, Riccardo , Pinto, Marcia, Pouplet, Caroline, Regli, Adrian , Roca, Oriol , Rosell, Jon, Ruan, Sheng‐Yuan , Sahu, Samir, Sales, Gabriele , Roman, Nandyelly San Juan, Sánchez‐Hurtado, Luis Alejandro , Santafe, Manel, Sanyal, Rhik, Shah, Bhagyesh, Silva, Monica, Simpson, Shannon, Singh, Atul Kumar , Singh, Lalit, Sosa, Miguel A., Srivastava, Anand, Szakmány, Tamás , Tabah, Alexis , León, José Andrés Tutillo , Wahlstrom, Carl, Hassan, Wan Mohd Nazaruddin Wan , Wang, Kuo‐Chuan , Wu, Jiayan , Yeh, Yu‐Chang , Young, Paul J.

Mayo Clinic

JAMA | March 23, 2021 | Volume: 325 | Issue: 12 | Pages: 1164

10.1001/jama.2021.1727 | PMID 33755076 Get It

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
Chen, Alice P. , Moore, Nancy, Zhao, Yingdong , Palmisano, Alida , Coyne, Geraldine O’Sullivan , Rosenberger, Christina L. , Simpson, Mel, Leong, Stephen , Foster, Jared C. , Konaté, Mariam M. , Das, Biswajit , Karlovich, Chris , Lih, Chih-Jian, Simon, Richard , Li, Ming-Chung, Doroshow, James H. , Polley, Eric, O'Sullivan Coyne, Geraldine , Kummar, Shivaani , Rubinstein, Larry , Williams, P. Mickey , Sims, David, Raghav, Kanwal , Meric‐Bernstam, Funda , Waqar, Saiama N , Lih, Chih‐Jian, Polley, Eric C. , Li, Ming‐Chung, Piekarz, Richard

Mayo Clinic

JCO Precision Oncology | January 12, 2021 | Volume: No volume available | Issue: 5 | Pages: 133-144

10.1200/po.20.00372 | PMID 33928209 Get It

PURPOSE This trial assessed the utility of applying tumor DNA sequencing to treatment selection for patients with advanced, refractory cancer and somatic mutations in one of four signaling pathways by comparing the efficacy of four study regimens that were either matched to the patient's aberrant pathway (experimental arm) or not matched to that pathway (control arm). MATERIALS AND METHODS Adult patients with an actionable mutation of interest were randomly assigned 2:1 to receive either (1) a study regimen identified to target the aberrant pathway found in their tumor (veliparib with temozolomide or adavosertib with carboplatin [DNA repair pathway], everolimus [PI3K pathway], or trametinib [RAS/RAF/MEK pathway]), or (2) one of the same four regimens, but chosen from among those not targeting that pathway. RESULTS Among 49 patients treated in the experimental arm, the objective response rate was 2% (95% CI, 0% to 10.9%). One of 20 patients (5%) in the experimental trametinib cohort had a partial response. There were no responses in the other cohorts. Although patients and physicians were blinded to the sequencing and random assignment results, a higher pretreatment dropout rate was observed in the control arm (22%) compared with the experimental arm (6%; P = .038), suggesting that some patients may have had prior tumor mutation profiling performed that led to a lack of participation in the control arm. CONCLUSION Further investigation, better annotation of predictive biomarkers, and the development of more effective agents are necessary to inform treatment decisions in an era of precision cancer medicine. Increasing prevalence of tumor mutation profiling and preference for targeted therapy make it difficult to use a randomized phase II design to evaluate targeted therapy efficacy in an advanced disease setting.
Holmes Tremor With Perirolandic Demyelinating Lesions
Bower, James H., Hassan, Anhar , Conway, Brittani L., Budhram, Adrian , Simpson, Hugh D. , Flanagan, Eoin P.

Mayo Clinic

Neurology | November 21, 2020 | Volume: 96 | Issue: 5 | Pages: 231-232

10.1212/wnl.0000000000011235 | PMID 33219140 Get It

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
Rhee, Frits van , Rossi, Jean‐François , Simpson, David , Cho, Seok‐Goo , Capra, Marcelo , Liu, Ting , Cavet, James, van Rhee, Frits , Cho, Seok-Goo , Fosså, Alexander , Dispenzieri, Angela , Kuruvilla, John , Goh, Yeow Tee , Casper, Corey , Wong, Raymond

Mayo Clinic

British Journal of Haematology | October 31, 2020 | Volume: 192 | Issue: 1 | Pages: No page available

10.1111/bjh.17177 | PMID 33128769 Get It

Abstract 37: Highly aggregated lung cancer families reveal a heterogeneous cause for a previous linkage signal on 6q
Moiz, Bilal A., Mandal, Diptasri , Gaba, Colette , Yang, Ping , You, Ming , Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Musolf, Anthony M. , Simpson, Claire L. , Andrade, Mariza de , Pinney, Susan M. , Amos, Christopher I. , Bailey‐Wilson, Joan E.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 37-37

10.1158/1538-7445.am2020-37 Get It

Abstract More Americans die every year of lung cancer than any other cancer. While the environmental risks for lung cancer are well understood, the genetic risk factors for this disease are not, even though it has been shown that lung cancer risk aggregates in families. Segregation analyses have confirmed the likelihood of rare, highly penetrant variants affecting lung cancer. Family studies offer a unique opportunity to identify such rare risk variants. We have previously identified a genome-wide significant risk locus for lung cancer using multipoint linkage analysis in highly aggregated lung cancer families. In this study, we performed targeted sequencing on this 6q23-6q27 region on 75 individuals from the 9 most strongly linked families. Parametric two-point linkage analysis using an autosomal dominant model with 10% penetrance for carriers and a 1% phenocopy rate and disease allele frequency of 1% was performed for each family. While we did not find any genome-wide significant results in any of the individual families, we did observe several interesting potential rare risk variants. First, we observed that the significant signal previously observed on 6q is recapitulated in these data but the location of the peak LOD is highly heterogeneous across families and it is likely that each family has a different risk gene. While most of the highest LOD scores were in noncoding variants, we did observe exonic variants with the highest LOD scores in two families (44 and 42). Both variants were rare, with a minor allele frequency (MAF) of approximately 1% and were in LPA and GPR126 respectively. Both these genes have been implicated somatically in lung cancer, however this is the first time that they have been implicated in the germline. While the other families have their highest LOD scores in noncoding variants, some of these genes are also good potential candidate genes including PARK2 (family 30), GRM1 (family 47), and PDE10A (family 102). All three genes have been implicated in lung cancer in some capacity, and this is the first time that GRM1 and PDE10A have been implicated as germline mutations. Again, all these variants are rare (MAF ⇐ 0.01) in the general population, which makes sense for a potential highly penetrant risk variant. In this study, we have elucidated that a previously identified risk locus on 6q25 is heterogeneous in the nine most strongly linked families, with different families appearing to be carrying different risk variants. Many of the top variants in each family are rare variants that are in good potential causal genes that have been identified for the first time here as germline risk variants for lung cancer. Further functional annotation is underway for these variants and some additional linkage analyses using other penetrance matrices may also be performed. Citation Format: Anthony M. Musolf, Claire L. Simpson, Bilal A. Moiz, Mariza de Andrade, Diptasri Mandal, Colette Gaba, Ping Yang, Ming You, Elena Y. Kupert, Marshall W. Anderson, Ann G. Schwartz, Susan M. Pinney, Christopher I. Amos, Joan E. Bailey-Wilson. Highly aggregated lung cancer families reveal a heterogeneous cause for a previous linkage signal on 6q [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 37.